Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $27,5M Series B financing. Participants include Wellington Partners Venture Capital, Aravis Venture Associates, Auriga Partners and Vinci Capital.

Proteon Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on a recombinant human elastase designed to improve arteriovenous fistula surgery outcomes in patients requiring chronic hemodialysis, closed on $12M, bringing the total Series B financing to $50M. Participants include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio, Vectis Healthcare & Life Science Fund, TVM Capital, [...]

Proteon Therapeutics (Waltham, MA) a clinical stage biopharmaceutical company focused on renal and vascular disease, closed a $38M Series B financing. Participants include MPM Capital, Vectis Healthcare & Life Sciences Fund, TVM Capital, Skyline Ventures, Prism VentureWorks and Intersouth Partners.

Ardian (Palo Alto, CA) a clinical-stage medical device company focused on catheter-based treatment for hypertension, chronic kidney disease and heart failure, closed a $47M Series C financing. Participants include Medtronic, Emergent Medical Partners, Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners.

Infacare Pharmaceutical (Trevose, PA) a specialty pharma company focused on the the acute neonatal and pediatric care closed a $28M Series financing. Participants include HealthCare Ventures, Longitude Capital, FirstMark Capital and Atlas Venture.

AlloCure (Germany, UT) a cell therapy company focused on acute kidney injury closed a $14.5M Series A financing. Participants include SV Life Sciences and Novo AS.

Cytochroma (Canada) clinical-stage specialty pharmaceutical company focused on products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease, closed a $45M Series C financing. Participants include Mitsubishi Tanabe Pharma Corporation, Vengrowth Advanced Life Sciences Fund, Caisse de Depot et Placement du Quebec, Novo, Canadian Medical Discoveries Fund, T2C2 Capital, GrowthWorks Canadian Fund, [...]

AM-Pharma (Netherlands) biopharmaceutical company developing endogenous proteins and peptides to combat acute renal failure, ulcerative colitis and hospital acquired infections, closed a $36M Series C financing. Participants include Forbion Capital Partners and Inventages Venture Capital.

Quark Pharmaceuticals (Fremont, CA) development-stage pharmaceutical company focused on discovering and developing novel RNAi therapeutics, closed a $27M Series B financing. Participants include SBI Investment Co.